Wintrust Investments LLC Cuts Holdings in Pfizer Inc. (NYSE:PFE)

Wintrust Investments LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 16.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,083 shares of the biopharmaceutical company’s stock after selling 3,544 shares during the period. Wintrust Investments LLC’s holdings in Pfizer were worth $783,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Thoroughbred Financial Services LLC lifted its stake in Pfizer by 4,297.8% in the second quarter. Thoroughbred Financial Services LLC now owns 2,656,678 shares of the biopharmaceutical company’s stock worth $265,668,000 after purchasing an additional 2,596,269 shares during the last quarter. Marshall Wace North America L.P. lifted its stake in Pfizer by 52.9% in the first quarter. Marshall Wace North America L.P. now owns 7,431,974 shares of the biopharmaceutical company’s stock worth $315,635,000 after purchasing an additional 2,571,626 shares during the last quarter. California Public Employees Retirement System lifted its stake in Pfizer by 14.0% in the fourth quarter. California Public Employees Retirement System now owns 20,333,138 shares of the biopharmaceutical company’s stock worth $887,541,000 after purchasing an additional 2,504,336 shares during the last quarter. Railway Pension Investments Ltd bought a new stake in Pfizer in the second quarter worth about $10,019,000. Finally, Fisher Asset Management LLC lifted its stake in Pfizer by 3.7% in the second quarter. Fisher Asset Management LLC now owns 44,133,251 shares of the biopharmaceutical company’s stock worth $1,911,852,000 after purchasing an additional 1,559,405 shares during the last quarter. Hedge funds and other institutional investors own 71.58% of the company’s stock.

PFE has been the subject of several analyst reports. Morgan Stanley downgraded shares of Pfizer from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $48.00 to $40.00 in a research note on Tuesday, July 30th. Bank of America downgraded shares of Pfizer from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 30th. JPMorgan Chase & Co. set a $46.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Monday, July 29th. Goldman Sachs Group reissued a “buy” rating and issued a $49.00 price objective on shares of Pfizer in a research note on Monday, June 17th. Finally, Credit Suisse Group reissued a “neutral” rating on shares of Pfizer in a research note on Monday, August 12th. Fourteen equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and an average price target of $46.67.

Shares of Pfizer stock traded up $0.20 on Thursday, hitting $35.07. 7,622,292 shares of the company traded hands, compared to its average volume of 35,261,488. The stock’s 50 day moving average price is $39.98 and its 200-day moving average price is $41.51. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 52 week low of $33.97 and a 52 week high of $46.47. The company has a market cap of $194.58 billion, a PE ratio of 11.69, a PEG ratio of 2.81 and a beta of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The firm had revenue of $13.26 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the previous year, the firm posted $0.77 earnings per share. The company’s revenue was down 1.5% on a year-over-year basis. As a group, research analysts anticipate that Pfizer Inc. will post 2.8 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd will be issued a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a yield of 4.11%. The ex-dividend date is Thursday, August 1st. Pfizer’s payout ratio is 48.00%.

In related news, EVP Frank A. Damelio sold 153,184 shares of Pfizer stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the transaction, the executive vice president now directly owns 489,647 shares of the company’s stock, valued at $21,588,536.23. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Alexander R. Mackenzie sold 30,000 shares of Pfizer stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the transaction, the insider now directly owns 80,094 shares in the company, valued at $3,524,136. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: How accurate is the Rule of 72?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit